1.中国中医科学院 医学实验中心,北京市中医药防治重大疾病基础研究重点实验室,北京 100700
2.赣南医科大学 科研中心,江西 赣州 341000
焦玥,博士,助理研究员,从事中药对于神经系统疾病研究,E-mail:jiaoyue_medicine@163.com
李涛,硕士,副研究员,从事中药药动学、中医药代谢组学等新技术研究,E-mail:hndxlitao@163.com
收稿:2024-05-28,
网络出版:2024-09-20,
纸质出版:2024-12-05
移动端阅览
焦玥,姜宇懋,王丹巧等.青藤碱对人脑胶质瘤的抑制作用及肿瘤内药代动力学特征[J].中国实验方剂学杂志,2024,30(23):179-186.
JIAO Yue,JIANG Yumao,WANG Danqiao,et al.Inhibitory Effect of Sinomenine on Human Glioblastoma and Its Pharmacokinetic Characteristics[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(23):179-186.
焦玥,姜宇懋,王丹巧等.青藤碱对人脑胶质瘤的抑制作用及肿瘤内药代动力学特征[J].中国实验方剂学杂志,2024,30(23):179-186. DOI: 10.13422/j.cnki.syfjx.20241442.
JIAO Yue,JIANG Yumao,WANG Danqiao,et al.Inhibitory Effect of Sinomenine on Human Glioblastoma and Its Pharmacokinetic Characteristics[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(23):179-186. DOI: 10.13422/j.cnki.syfjx.20241442.
目的
2
观察青藤碱(sinomenine)对人脑胶质瘤的抑制作用及在脑胶质瘤内的药代动力学特征。
方法
2
构建稳定表达荧光素酶的脑胶质瘤U87细胞系,脑内接种建立同时用于药效学和药代动力学研究的小鼠胶质瘤模型。药效学部分:模型小鼠随机分为模型组和青藤碱低、中、高剂量组(50、100、150 mg·kg
-1
),腹腔注射给药14 d,观察脑内肿瘤荧光值,分析其对脑胶质瘤增殖的抑制作用;取脑肿瘤及肿瘤周围脑组织,蛋白免疫印迹法(Western blot)检测血管内皮生长因子A(VEGFA)、药物转运体P-糖蛋白(P-gp)和乳腺癌耐药蛋白(BCRP)及闭合蛋白(Occludin)的表达水平。药代动力学部分:小鼠分为正常给药组(50 mg·kg
-1
)和模型给药组(50、100、150 mg·kg
-1
),青藤碱单次腹腔注射后,微透析技术活体采集脑肿瘤细胞外液,每15 min收集1次,共收集至给药后6 h。高效液相色谱-质谱联用法(HPLC-MS/MS)检测透析液中青藤碱浓度,计算药代动力学参数,分析青藤碱在脑和脑胶质瘤内的药代动力学特征。
结果
2
与模型组比较,青藤碱给药14 d后脑内肿瘤荧光值明显降低(
P
<
0.05),并呈一定的剂量依赖性。青藤碱可抑制肿瘤周围VEGF的升高和Occludin的降解,抑制胶质瘤VEGF、P-gp、BCRP蛋白表达。青藤碱单次给药后,在7.5 min即可到达脑组织和肿瘤组织。和正常组比较,肿瘤内
C
max
、AUC均明显升高,
T
max
缩短(从1.63 h缩短至0.71 h),CLz/
F
降低。在50~150 mg·kg
-1
剂量范围内,脑胶质瘤内的青藤碱呈现一定的线性药代动力学过程。
结论
2
青藤碱对于脑胶质瘤具有明显的抑制作用,抑制VEGF的增高和药物转运蛋白的外排,降低肿瘤侵袭,维持血脑屏障完整。青藤碱可以快速通过血肿瘤屏障并达峰,在肿瘤内具有线性药代动力学特征。
Objective
2
To observe the inhibitory effect of sinomenine on human glioblastoma and its pharmacokinetic characteristics in glioblastoma.
Method
2
A human glioblastoma U87 cell line stably expressing luciferase was constructed, and a mouse glioma model was established for use in both pharmacodynamic and pharmacokinetic studies. Pharmacodynamics: Model mice were randomly divided into model group and sinomenine low-, medium-, and high-dose g
roups (50, 100, 150 mg·kg
-1
). Sinomenine was administered intraperitoneally for 14 days. The fluorescence value of brain tumors was observed to analyze its inhibitory effect on glioblastoma proliferation. Brain tumors and the surrounding brain tissue were collected, and the expression levels of vascular endothelial growth factor A (VEGFA), P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and Occludin were detected by Western blot. Pharmacokinetics: Mice were divided into a normal group (50 mg·kg
-1
) and model groups (50, 100, 150 mg·kg
-1
). After a single intraperitoneal injection of sinomenine, extracellular fluid from brain tumors was collected
in vivo
by microdialysis every 15 min for 6 h. Sinomenine concentrations in the dialysate were detected by HPLC-MS/MS, and pharmacokinetic parameters were calculated to analyze pharmacokinetic characteristics of sinomenine in the brain and glioblastoma.
Result
2
Compared with model group, after 14 days of sinomenine administration, the fluorescence value of brain tumors significantly decreased (
P
<
0.05) in a dose-dependent manner. Sinomenine inhibited the increase in VEGF and the degradation of Occludin in the tissue surrounding the tumor and inhibited the expression of VEGF, P-gp, and BCRP in glioblastoma. After a single administration, sinomenine was detected in brain and tumor tissues within 7.5 min. Compared with normal group, the
C
max
and AUC in the tumor significantly increased,
T
max
shortened (from 1.63 h to 0.71 h), and CLz/
F
decreased. In the dose range of 50-150 mg·kg
-1
, sinomenine exhibited a linear pharmacokinetic process in glioblastoma.
Conclusion
2
Sinomenine has a significant inhibitory effect on glioblastoma, which can inhibit VEGF elevation and drug transporter efflux, reduce tumor invasion, and maintain the integrity of the blood-brain barrier. Sinomenine can rapidly cross the blood-tumor barrier, reach peak concentration, and exhibit linear pharmacokinetic characteristics in the tumor.
SCHAFF L R , MELLINGHOFF I K . Glioblastoma and other primary brain malignancies in adults:A review [J]. JAMA , 2023 , 329 ( 7 ): 574 - 587 .
DAPASH M , HOU D , CASTRO B , et al . The interplay between glioblastoma and its microenvironment [J]. Cells , 2021 , 10 ( 9 ): 2257 .
KHATAMI S H , KARAMI N , TAHERI-ANGANEH M , et al . Exosomes:Promising delivery tools for overcoming blood-brain barrier and glioblastoma therapy [J]. Mol Neurobiol , 2023 , 60 ( 8 ): 4659 - 4678 .
JIANG Y M , JIAO Y , WANG Z G , et al . Sinomenine hydrochloride inhibits human glioblastoma cell growth through reactive oxygen species generation and autophagy-lysosome pathway activation: An in vitro and in vivo study [J]. Int J Mol Sci , 2017 , 8 ( 9 ): 1945 .
JIANG Y M , JIAO Y , LIU Y , et al . Sinomenine hydrochloride inhibits the metastasis of human glioblastoma cells by suppressing the expression of matrix metalloproteinase-2/-9 and reversing the endogenous and exogenous epithelial-mesenchymal transition [J]. Int J Mol Sci , 2018 , 19 ( 3 ): 844 .
王爽 , 许坚吉 , 刘晓霓 , 等 . 荧光素酶生物发光报告体系的优化及在肝癌荷瘤裸鼠模型中的应用 [J]. 实用肝脏病杂志 , 2019 , 22 ( 4 ): 482 - 485 .
ZHU H M , GU J H , XIE Y , et al . Hydroxycamptothecin liposomes based on thermal and magnetic dual-responsive system:Preparation, in vitro and in vivo antitumor activity,microdialysis-based tumor pharmacokinetics [J]. J Drug Target , 2018 , 26 ( 4 ): 345 - 356 .
李涛 , 赵小亮 , 高天乐 , 等 . 大鼠血液和脑组织液中游离型青藤碱、川芎嗪、加巴喷丁、扑热息痛、普瑞巴林和阿米替林的微透析液取样及HPLC-MS/MS定量方法研究 [J]. 药学学报 , 2020 , 55 ( 9 ): 2198 - 2206 .
ZHU J , ZHU H , GAO J . The anti-tumor potential of sinomenine:A narrative review [J]. Transl Cancer Res , 2023 , 12 ( 9 ): 2393 - 2404 .
TERSTAPPEN G C , MEYER A H , BELL R D , et al . Strategies for delivering therapeutics across the blood-brain barrier [J]. Nat Rev Drug Discov , 2021 , 20 ( 5 ): 362 - 383 .
彭雨 , 陈维良 , 张毓雯 , 等 . 药物跨血脑屏障治疗脑胶质瘤的研究进展 [J]. 赣南医学院学报 , 2023 , 43 ( 4 ): 350 - 357 .
STEEG P S . The blood-tumour barrier in cancer biology and therapy [J]. Nat Rev Clin Oncol , 2021 , 18 ( 11 ): 696 - 714 .
AHIR B K , ENGELHARD H H , LAKKA S S . Tumor development and angiogenesis in adult brain tumor: Glioblastoma [J]. Mol Neurobiol , 2020 , 57 ( 5 ): 2461 - 2478 .
CHATTERJEE S , DESHPANDE A A , SHEN H . Recent advances in the in vitro and in vivo methods to assess impact of p-glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition [J]. Biopharm Drug Dispos , 2023 , 44 ( 1 ): 7 - 25 .
KHEOANE P S , ENSLIN G M , TARIRAI C . Determination of effective concentrations of drug absorption enhancers using in vitro and ex vivo models [J]. Eur J Pharm Sci , 2021 , 167 : 106028 .
张如洪 , 陈亮 . 青藤碱对更昔洛韦肠吸收的促进作用 [J]. 中国医院药学杂志 , 2012 , 32 ( 18 ): 1420 - 1423 .
LI X T , TANG W , XIE H J , et al . The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma [J]. J Liposome Res , 2019 , 29 ( 1 ): 21 - 34 .
李涛 , 赵小亮 , 聂颖兰 , 等 . CQ止痛复方中青藤碱和川芎嗪的脑通透性研究 [J]. 药学学报 , 2019 , 54 ( 12 ): 2308 - 2315 .
0
浏览量
62
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
